Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets.
R B WarrenBruce StroberJonathan Ian SilverbergE GuttmanP AndresJ FeldingDeniz TutkunkardasK KjøllerM O A SommerLars Einar FrenchPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Orismilast IR displayed higher efficacy compared to placebo in patients with moderate-to-severe psoriasis at week 16. Orismilast MR had similar PK properties and fewer GI disorders compared to the IR formulation in healthy participants. Future development of orismilast will be based on the MR formulation.